Eagle Pharmaceuticals, Inc. stock is down -38.68% since 30 days ago. The next earnings date is Dec 22, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 December’s closed higher than November.
Eagle Pharmaceuticals, Inc. focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology. The company offers Ryanodex for malignant hyperthermia; Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure.